Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:TRDA

Entrada Therapeutics Q2 2025 Earnings Report

Entrada Therapeutics logo
$7.46 +0.01 (+0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$7.47 +0.01 (+0.13%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Entrada Therapeutics EPS Results

Actual EPS
-$1.04
Consensus EPS
-$0.86
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Entrada Therapeutics Revenue Results

Actual Revenue
$1.98 million
Expected Revenue
$8.17 million
Beat/Miss
Missed by -$6.19 million
YoY Revenue Growth
N/A

Entrada Therapeutics Announcement Details

Quarter
Q2 2025
Date
8/6/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Slide Deck

Entrada Therapeutics' Q2 2025 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

Entrada Therapeutics' Q2 2025 Press ReleasePress Release
(8-K)
Entrada Therapeutics' Q2 2025 Quarterly reportQuarterly report
(10-Q)

Entrada Therapeutics Earnings Headlines

Q3 EPS Estimate for Entrada Therapeutics Lowered by Analyst
August 14 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959266
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 52,317 Shares
August 11 at 4:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30954622
Trump’s April 2027 Deadline Has Wallstreet Scrambling.
The DTCC settles nearly every U.S. stock trade, but the old system takes three days and requires $12 billion in idle cash as a safety cushion. A new settlement grid now processes over 100,000 trades a day with instant, tamper-proof records. Trump has plans to move the entire $382 trillion financial system onto this infrastructure by April 2027. BlackRock's new fund on the grid hit $2.8 billion in assets in three months, JPMorgan runs $2 billion a day through it, and Goldman Sachs, Citi, Bank of America and Wells Fargo have announced integration plans.tc pixel
August 14 at 1:00 AM  |  Awesomely (Ad)
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 52,317 Shares
August 11 at 4:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30954611
Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 92,444 Shares of Stock
August 11 at 4:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30954600
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/entrada-therapeutics-reports-second-quarter-110000613.html
See More Entrada Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ:TRDA) (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas.

Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.

View Entrada Therapeutics Profile
Earnings Tools